Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Methylphenylisoxazolyl Penicillin
2. Oxacillin
3. Oxacillin, Monosodium Salt, Anhydrous
4. Oxacillin, Monosodium Salt, Monohydrate
5. Oxacillin, Sodium
6. Oxazocilline
7. Penicillin, Methylphenylisoxazolyl
8. Prostaphlin
9. Sodium Oxacillin
10. Sodium, Oxacillin
1. Oxacillin Sodium Salt
2. 1173-88-2
3. Oxabel
4. Prostaphlin
5. Bactocill
6. Sodium Oxacillin
7. Oxacillin Sodium Anhydrous
8. Bristopen
9. Micropenin
10. Resistopen
11. Staphcillin V
12. Oxacillin (sodium Salt)
13. Chebi:52134
14. 4twd2995up
15. Oxabel Sodium Salt
16. Monosodium Oxacillin
17. Sq-16423
18. Anhydrous Oxacillin Sodium
19. Sodium Methylphenylisoaxazolylpenicillin
20. Oxacillin Sodium (van)
21. Sodium (2s,5r,6r)-3,3-dimethyl-6-(5-methyl-3-phenylisoxazole-4-carboxamido)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
22. 5-methyl-3-phenyl-4-isoxazolyl Penicillin, Sodium
23. Nsc-527712
24. Brl 1400
25. Oxacillin Sodium [usp]
26. 7240-38-2
27. Einecs 214-636-3
28. Nsc 527712
29. Unii-4twd2995up
30. Bactocill In Plastic Container
31. Ncgc00183361-01
32. Chembl693
33. Dsstox_cid_28906
34. Dsstox_rid_83174
35. Dsstox_gsid_48980
36. Schembl41165
37. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, Monosodium Salt, (2s-(2alpha,5alpha,6beta))-
38. Mls000069542
39. Dtxsid9048980
40. Oxacillin Sodium [who-dd]
41. Hms3714g11
42. Hy-b0925
43. Sodium;(2s,5r,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
44. Tox21_113439
45. Bdbm50248015
46. Akos015896457
47. Ccg-220675
48. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, Monosodium Salt, (2s,5r,6r)-
49. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3,3-dimethyl-6-(5-methyl-3-phenyl-4-isoxazolecarboxamido)-7-oxo-, Monosodium Salt
50. As-82071
51. Smr000058841
52. Sodium (2s-(2alpha,5alpha,6beta))-3,3-dimethyl-6-(((5-methyl-3-phenylisoxazol-4-yl)carbonyl)amino)-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
53. Anhydrous Oxacillin Sodium [mart.]
54. Cas-1173-88-2
55. O0353
56. D97506
57. W-108566
58. Q27123265
59. Oxacillin Sodium, Antibiotic For Culture Media Use Only
60. Sodium 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanate
61. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, Sodium Salt (1:1), (2s,5r,6r)-
62. Sodium 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylate
| Molecular Weight | 423.4 g/mol |
|---|---|
| Molecular Formula | C19H18N3NaO5S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 423.08648614 g/mol |
| Monoisotopic Mass | 423.08648614 g/mol |
| Topological Polar Surface Area | 141 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 687 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Bactocill in plastic container |
| Drug Label | Oxacillin for Injection, USP is a semisynthetic penicillin antibiotic derived from the penicillin nucleus, 6-amino-penicillanic acid. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). It is the sodium salt in parenteral do... |
| Active Ingredient | Oxacillin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 20mg base/ml; eq 40mg base/ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 2 of 4 | |
|---|---|
| Drug Name | Oxacillin sodium |
| Active Ingredient | Oxacillin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2gm base/vial; eq 10gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Aurobindo Pharma; Sandoz; Sagent Pharms; Agila Speclts |
| 3 of 4 | |
|---|---|
| Drug Name | Bactocill in plastic container |
| Drug Label | Oxacillin for Injection, USP is a semisynthetic penicillin antibiotic derived from the penicillin nucleus, 6-amino-penicillanic acid. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). It is the sodium salt in parenteral do... |
| Active Ingredient | Oxacillin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 20mg base/ml; eq 40mg base/ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 4 of 4 | |
|---|---|
| Drug Name | Oxacillin sodium |
| Active Ingredient | Oxacillin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2gm base/vial; eq 10gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Aurobindo Pharma; Sandoz; Sagent Pharms; Agila Speclts |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Oxacillin Sodium Monohydrate, Sterile
Certificate Number : CEP 2007-363 - Rev 04
Status : Valid
Issue Date : 2023-11-30
Type : Chemical
Substance Number : 2260
Certificate Number : CEP 2007-349 - Rev 06
Status : Valid
Issue Date : 2023-11-30
Type : Chemical
Substance Number : 2260
Oxacillin Sodium Monohydrate, Powder And Compact...
Certificate Number : R1-CEP 2006-251 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2019-04-24
Type : Chemical
Substance Number : 2260
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
Oxacillin Sodium Monohydrate Ph. Eur.
Date of Issue : 2022-08-02
Valid Till : 2025-07-02
Written Confirmation Number : WC-0121
Address of the Firm : Plot No. 68-70, 73-91, 95, 96, 260, 261, IDA, Pashamylaram (village), Patancheru...
Oxacillin Sodium Monohydrate Ph. Eur.
Date of Issue : 2022-08-02
Valid Till : 2025-07-02
Written Confirmation Number : WC-0121
Address of the Firm : Plot No. 68-70, 73-91, 95, 96, 260, 261, IDA, Pashamylaram (village), Patancheru...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Parenteral
Controlled & Modified Release
Fillers, Diluents & Binders
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
93
PharmaCompass offers a list of Oxacillin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Oxacillin Sodium manufacturer or Oxacillin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oxacillin Sodium manufacturer or Oxacillin Sodium supplier.
PharmaCompass also assists you with knowing the Oxacillin Sodium API Price utilized in the formulation of products. Oxacillin Sodium API Price is not always fixed or binding as the Oxacillin Sodium Price is obtained through a variety of data sources. The Oxacillin Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Bristopen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bristopen, including repackagers and relabelers. The FDA regulates Bristopen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bristopen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bristopen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bristopen supplier is an individual or a company that provides Bristopen active pharmaceutical ingredient (API) or Bristopen finished formulations upon request. The Bristopen suppliers may include Bristopen API manufacturers, exporters, distributors and traders.
click here to find a list of Bristopen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bristopen DMF (Drug Master File) is a document detailing the whole manufacturing process of Bristopen active pharmaceutical ingredient (API) in detail. Different forms of Bristopen DMFs exist exist since differing nations have different regulations, such as Bristopen USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bristopen DMF submitted to regulatory agencies in the US is known as a USDMF. Bristopen USDMF includes data on Bristopen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bristopen USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bristopen suppliers with USDMF on PharmaCompass.
A Bristopen CEP of the European Pharmacopoeia monograph is often referred to as a Bristopen Certificate of Suitability (COS). The purpose of a Bristopen CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Bristopen EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Bristopen to their clients by showing that a Bristopen CEP has been issued for it. The manufacturer submits a Bristopen CEP (COS) as part of the market authorization procedure, and it takes on the role of a Bristopen CEP holder for the record. Additionally, the data presented in the Bristopen CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Bristopen DMF.
A Bristopen CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Bristopen CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Bristopen suppliers with CEP (COS) on PharmaCompass.
A Bristopen written confirmation (Bristopen WC) is an official document issued by a regulatory agency to a Bristopen manufacturer, verifying that the manufacturing facility of a Bristopen active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bristopen APIs or Bristopen finished pharmaceutical products to another nation, regulatory agencies frequently require a Bristopen WC (written confirmation) as part of the regulatory process.
click here to find a list of Bristopen suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bristopen as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bristopen API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bristopen as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bristopen and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bristopen NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bristopen suppliers with NDC on PharmaCompass.
Bristopen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bristopen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bristopen GMP manufacturer or Bristopen GMP API supplier for your needs.
A Bristopen CoA (Certificate of Analysis) is a formal document that attests to Bristopen's compliance with Bristopen specifications and serves as a tool for batch-level quality control.
Bristopen CoA mostly includes findings from lab analyses of a specific batch. For each Bristopen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bristopen may be tested according to a variety of international standards, such as European Pharmacopoeia (Bristopen EP), Bristopen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bristopen USP).
